U.S. Paper and Forestry Products Stock News

NYSE:AIZ
NYSE:AIZInsurance

Assurant (AIZ) Stock May Be A Bargain At Today’s Price

Assurant stock has delivered a strong 112.2% return over the past three years, yet the valuation signals are split, with the Excess Returns intrinsic value estimate suggesting the shares trade below intrinsic value while earnings based multiples point to a richer price. Assurant's 112.2% three-year return highlights how strongly the share price has rewarded long-term holders. Future valuation may be supported if the company can sustain reliable cash generation, although any pressure on...
NYSE:CIEN
NYSE:CIENCommunications

Ciena (CIEN) Is Up 9.4% After Quantum‑Safe 1.6 Tb/s Network Milestone With e& UAE

In early August 2026, e& UAE announced it had deployed Ciena Corporation’s next-generation DWDM, WaveLogic 6 Extreme optics, and Navigator automation to build a higher-capacity, future-ready national network, while Ciena also took part in a live commercial trial of 1.6 Tb/s quantum-safe encrypted connectivity with Quantum Corridor and Toshiba International Corporation. Together, these developments highlight Ciena’s role in enabling both ultra-high-capacity transport and quantum-resilient...
NYSE:TJX
NYSE:TJXSpecialty Retail

TJX Companies (TJX) Gains Momentum But Is The Growth Story Already Priced In

Recent momentum signals and estimate revisions TJX Companies (TJX) has drawn fresh investor attention after achieving a Momentum Style Score of B and receiving a Zacks Rank of #2, alongside positive revisions to earnings estimates for the current and next fiscal year. See our latest analysis for TJX Companies. TJX Companies shares trade at US$161.36, with a 30 day share price return of 5.61% and a 1 year total shareholder return of 24.33%. The 5 year total shareholder return of 145.30% points...
NYSE:EHC
NYSE:EHCHealthcare

Encompass Health (EHC) Is Up 12.7% After Raising 2026 Guidance And Completing Major Buyback Program – Has The Bull Case Changed?

Encompass Health reported past second-quarter 2026 results with net operating revenue of US$1,597.4 million and net income of US$153.9 million, alongside higher earnings per share versus a year earlier. The company also raised its full-year 2026 revenue guidance and completed a long-running share repurchase program that has retired nearly one-tenth of its shares. We’ll now examine how Encompass Health’s raised 2026 revenue guidance shapes its investment narrative and what it may mean for...
NasdaqGS:SNEX
NasdaqGS:SNEXCapital Markets

Is StoneX Group (SNEX) Quietly Rewriting Its Core Strategy Through R.J. O’Brien Integration Progress?

StoneX Group Inc. recently reported past third-quarter 2026 results, with revenue rising to US$40.19 billion and net income reaching US$127.9 million, while earnings per share from continuing operations roughly doubled versus a year earlier. Alongside this earnings strength, StoneX is deepening its payments reach through a new cross-border partnership with South Korea’s Shinhan Bank and progressing cost synergies from the R.J. O’Brien acquisition. We’ll now examine how StoneX’s stronger...
NasdaqGS:IBKR
NasdaqGS:IBKRCapital Markets

How Brazil Futures Access and Expanded AI Connectivity At Interactive Brokers Group (IBKR) Has Changed Its Investment Story

Interactive Brokers Group recently expanded access to Brazil’s B3 exchange, allowing eligible clients outside Brazil to trade both equities and futures, and also filed a shelf registration for its common shares. The company has also widened its Model Context Protocol-based AI integration, letting clients link a broad range of AI tools to analyze portfolios, research investments, and draft trade instructions securely across its platforms. We’ll now examine how this expansion into Brazilian...
NasdaqCM:PRCH
NasdaqCM:PRCHInsurance

Porch Group (PRCH) Is Up 9.7% After Strong Q2 Profit, 2026 Upgrade and ESOP Shelf Filing

In late July 2026, Porch Group, Inc. reported second-quarter sales of US$140.88 million and net income of US$5.6 million, alongside filing a US$28.428 million shelf registration for 2,300,000 common shares tied to an ESOP-related offering. The combination of stronger quarterly profitability, higher full-year guidance and an ESOP-linked shelf filing highlights how Porch is pairing operational progress with added flexibility in its capital structure and employee incentives. With Porch...
NasdaqGS:SWKS
NasdaqGS:SWKSSemiconductor

Skyworks Solutions (SWKS) Buyback And Dividend Shift Put Valuation Back In Focus

Skyworks Solutions (SWKS) is back in focus after Q3 FY2026 results showed year over year pressure on revenue and net income, alongside a decision to halt quarterly dividends and launch a new US$2b share repurchase plan. See our latest analysis for Skyworks Solutions. Skyworks Solutions shares have reacted strongly to the latest update, with a 1 day share price return of 5.66% and a 30 day share price return of 20.74%. The 1 year total shareholder return of 3.53% sits against a 3 year total...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

TransMedics Group (TMDX) Could Be 41% Undervalued As Earnings And Guidance Land

TransMedics Group (TMDX) is back in focus after reporting second quarter 2026 results on 4 August, pairing higher revenue with a lower net income figure and a small upward tweak to full year guidance. See our latest analysis for TransMedics Group. The earnings release and higher full year revenue guidance help explain why TransMedics Group’s recent momentum is strong, with a 30 day share price return of 19.09% and a 90 day share price return of 23.66%. This is despite the year to date share...
NasdaqGM:PVLA
NasdaqGM:PVLABiotechs

Palvella Therapeutics (PVLA) Earnings And QTORIN Hopes Keep Undervaluation In Focus

Palvella Therapeutics earnings and new shelf filing set the tone Palvella Therapeutics (PVLA) reported second quarter 2026 results on 4 August, with net loss and loss per share both wider than a year earlier. The company also filed a new shelf registration tied to an ESOP related offering. See our latest analysis for Palvella Therapeutics. The earnings release and new ESOP related shelf registration came alongside very strong momentum in Palvella Therapeutics' stock. The latest close at...